I'm LongbridgeAI, I can summarize articles.9M revenue grew 27.0% and reported profit attributable to shareholders rose 101.5%, supported by finished-drug sales and AstraZeneca licence income. Bulk products and functional food declined amid price, competition and procurement pressures.
Original document: CSPC Pharmaceutical Group Limited [1093] Earnings Release — Nov. 18 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
